Effect of vasoactive intestinal peptide on pacemaker location and heart rate in the dog atrium.

Pintér A, Nadeau R, Dandan N, Pagé PL

Canadian journal of physiology and pharmacology1 Apr 1998Cited by 2 (Europe PMC)

PMID9795756DOI10.1139/cjpp-76-4-457PepBankPUB-09795756

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In anesthetized dogs, VIP by artery perfusion or intravenous injection shifted the pacemaker site to the region of Bachmann's bundle in a third of preparations; in two thirds it stayed in the sinus node area.
In plain wordsIn dogs, VIP moved the heart's pacemaker site to Bachmann's bundle in a third of preparations; in two thirds it stayed in the sinus node.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
MixedAtrial pacemaker site shift after VIP
Study
dogn = 9
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · sinus node artery perfusion or intravenousAs given in this study (dog).
Source sentences
Summary
The perfusion of VIP into the SNA as well as the intravenous injection of VIP induced a shift of the pacemaker site to the region of Bachmann's bundle in a third of the preparations, while the pacemaker remained in the sinus node area in two thirds.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was either injected intravenously (300 pmol.kg-1) or perfused (1 nmol in 1 min) into the sinus node artery (SNA) in anesthetized dogs to study its effect on subsidiary atrial pacemakers.
Report a problemFND-0979575605
02AnimalAnimal study (in vivo)Efficacy outcome
In anesthetized dogs, VIP perfused into the sinus node artery increased heart rate by 29%.
In plain wordsIn dogs, VIP given into the sinus node artery raised heart rate by 29%.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseHeart rate after VIP perfusion into the sinus node artery
Study
dogn: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
1 nmol in 1 min · sinus node artery perfusionAs given in this study (dog).
Measurements
Heart rate change
29%
sinus node artery perfusion
Source sentences
Summary
When VIP was perfused into the SNA or injected intravenously, heart rate increased by 29 +/- 16% and 12 +/- 12%, and blood pressure decreased by 16 +/- 15 mmHg (1 mmHg = 133.3 Pa) and 24 +/- 18 mmHg, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was either injected intravenously (300 pmol.kg-1) or perfused (1 nmol in 1 min) into the sinus node artery (SNA) in anesthetized dogs to study its effect on subsidiary atrial pacemakers.
Report a problemFND-0979575601
03AnimalAnimal study (in vivo)Efficacy outcome
In anesthetized dogs, intravenous VIP increased heart rate by 12%.
In plain wordsIn dogs, VIP injected into a vein raised heart rate by 12%.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseHeart rate after intravenous VIP
Study
dogn: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
300 pmol/kg · intravenousAs given in this study (dog).
Measurements
Heart rate change
12%
intravenous injection
Source sentences
Summary
When VIP was perfused into the SNA or injected intravenously, heart rate increased by 29 +/- 16% and 12 +/- 12%, and blood pressure decreased by 16 +/- 15 mmHg (1 mmHg = 133.3 Pa) and 24 +/- 18 mmHg, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was either injected intravenously (300 pmol.kg-1) or perfused (1 nmol in 1 min) into the sinus node artery (SNA) in anesthetized dogs to study its effect on subsidiary atrial pacemakers.
Report a problemFND-0979575602
04AnimalAnimal study (in vivo)Efficacy outcome
In anesthetized dogs, VIP perfused into the sinus node artery lowered blood pressure by 16 mmHg.
In plain wordsIn dogs, VIP given into the sinus node artery lowered blood pressure by 16 mmHg.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseBlood pressure after VIP perfusion into the sinus node artery
Study
dogn: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
1 nmol in 1 min · sinus node artery perfusionAs given in this study (dog).
Measurements
Blood pressure change
−16 mmHg
sinus node artery perfusion
Source sentences
Summary
When VIP was perfused into the SNA or injected intravenously, heart rate increased by 29 +/- 16% and 12 +/- 12%, and blood pressure decreased by 16 +/- 15 mmHg (1 mmHg = 133.3 Pa) and 24 +/- 18 mmHg, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was either injected intravenously (300 pmol.kg-1) or perfused (1 nmol in 1 min) into the sinus node artery (SNA) in anesthetized dogs to study its effect on subsidiary atrial pacemakers.
Report a problemFND-0979575603
05AnimalAnimal study (in vivo)Efficacy outcome
In anesthetized dogs, intravenous VIP lowered blood pressure by 24 mmHg.
In plain wordsIn dogs, VIP injected into a vein lowered blood pressure by 24 mmHg.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseBlood pressure after intravenous VIP
Study
dogn: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
300 pmol/kg · intravenousAs given in this study (dog).
Measurements
Blood pressure change
−24 mmHg
intravenous injection
Source sentences
Summary
When VIP was perfused into the SNA or injected intravenously, heart rate increased by 29 +/- 16% and 12 +/- 12%, and blood pressure decreased by 16 +/- 15 mmHg (1 mmHg = 133.3 Pa) and 24 +/- 18 mmHg, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was either injected intravenously (300 pmol.kg-1) or perfused (1 nmol in 1 min) into the sinus node artery (SNA) in anesthetized dogs to study its effect on subsidiary atrial pacemakers.
Report a problemFND-0979575604
06AnimalAnimal study (in vivo)Efficacy outcome
In anesthetized dogs, isoproterenol perfusion into the sinus node artery produced a heart rate increase of 32%, not significantly different from the VIP increase.
In plain wordsIn dogs, VIP and isoproterenol raised heart rate by a similar amount.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeHeart rate increase with VIP versus isoproterenol
Study
dogn: not reported in source
Comparator
Isoproterenol
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · sinus node artery perfusionAs given in this study (dog).
Measurements
Heart rate change with isoproterenol
32%
sinus node artery perfusion
Source sentences
Summary
A perfusion of isoproterenol into the SNA produced a similar heart rate increase (32 +/- 14%, NS vs. VIP)
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was either injected intravenously (300 pmol.kg-1) or perfused (1 nmol in 1 min) into the sinus node artery (SNA) in anesthetized dogs to study its effect on subsidiary atrial pacemakers.
Report a problemFND-0979575606
07AnimalAnimal study (in vivo)Efficacy outcome
In anesthetized dogs, the pacemaker location response to VIP differed significantly from the response to isoproterenol.
In plain wordsIn dogs, VIP changed the heart's pacemaker location in a different way than isoproterenol did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablePacemaker location response to VIP versus isoproterenol
Study
dogn: not reported in source
Comparator
Isoproterenol
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · sinus node artery perfusionAs given in this study (dog).
Source sentences
Summary
The response to VIP in the location of the pacemaker was significantly different from the response to isoproterenol.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was either injected intravenously (300 pmol.kg-1) or perfused (1 nmol in 1 min) into the sinus node artery (SNA) in anesthetized dogs to study its effect on subsidiary atrial pacemakers.
Report a problemFND-0979575607
08AnimalAnimal study (in vivo)Efficacy outcome
In anesthetized dogs, repeated VIP perfusions at 10, 25 and 40 min raised heart rate by only 2%, 14% and 10%, a significantly smaller effect than the first dose (tachyphylaxis).
In plain wordsIn dogs, repeated VIP doses raised heart rate less than the first dose, which shows a fading effect.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseHeart rate response to repeated VIP perfusions at 10, 25 and 40 min
Study
dogn: not reported in source
Comparator
First VIP administration
Outcome group
Heart function · Cardiovascular
Studied dose
1 nmol in 1 min · sinus node artery perfusionAs given in this study (dog).
Measurements
Heart rate increase
2%
10 min interval
Heart rate increase
14%
25 min interval
Heart rate increase
10%
40 min interval
Source sentences
Summary
Repeated perfusions of VIP into the SNA after 10-, 25-, 40-, and 60-min intervals produced 2 +/- 13% (p < 0.005 vs. the effect of first VIP administration), 14 +/- 12% (p < 0.05), 10 +/- 12% (p < 0.05) and 30 +/- 13% (NS) heart rate increases, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was either injected intravenously (300 pmol.kg-1) or perfused (1 nmol in 1 min) into the sinus node artery (SNA) in anesthetized dogs to study its effect on subsidiary atrial pacemakers.
Report a problemFND-0979575608
09AnimalAnimal study (in vivo)Efficacy outcome
In anesthetized dogs, the heart rate increase after a VIP perfusion repeated at 60 min (30%) was not significantly different from the first dose.
In plain wordsIn dogs, a VIP dose repeated after 60 minutes raised heart rate about as much as the first dose.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeHeart rate response to repeated VIP perfusion at 60 min
Study
dogn: not reported in source
Comparator
First VIP administration
Outcome group
Heart function · Cardiovascular
Studied dose
1 nmol in 1 min · sinus node artery perfusionAs given in this study (dog).
Measurements
Heart rate increase
30%
60 min interval
Source sentences
Summary
Repeated perfusions of VIP into the SNA after 10-, 25-, 40-, and 60-min intervals produced 2 +/- 13% (p < 0.005 vs. the effect of first VIP administration), 14 +/- 12% (p < 0.05), 10 +/- 12% (p < 0.05) and 30 +/- 13% (NS) heart rate increases, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was either injected intravenously (300 pmol.kg-1) or perfused (1 nmol in 1 min) into the sinus node artery (SNA) in anesthetized dogs to study its effect on subsidiary atrial pacemakers.
Report a problemFND-0979575609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.